PUBLISHER: The Business Research Company | PRODUCT CODE: 1680813
PUBLISHER: The Business Research Company | PRODUCT CODE: 1680813
Acute bacterial skin and skin structure infections (ABSSSIs) represent a category of skin infections caused by bacteria impacting both the skin and underlying tissues, resulting in symptoms such as redness, swelling, pain, and increased warmth in the affected region. Medical interventions, including antibiotic treatments, are employed to prevent complications and facilitate recovery in cases ranging from mild to severe infections.
The primary classifications of acute bacterial skin and skin structure infections encompass hospital-acquired ABSSSIs and community-acquired ABSSSIs. Hospital-acquired ABSSSIs manifest as infections of the skin and underlying tissues that develop due to medical care or hospital stays. Active ingredients in treatments include delafloxacin, vancomycin, ceftaroline fosamil, oritavancin, tedizolid, daptomycin, tigecycline, linezolid, and others, with administration options including oral, parenteral, and topical routes. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, addressing various applications such as cellulitis, abscesses, surgical wounds, and traumatic wounds.
The acute bacterial skin and skin structure infections market research report is one of a series of new reports from The Business Research Company that provides acute bacterial skin and skin structure infections market statistics, including acute bacterial skin and skin structure infections industry global market size, regional shares, competitors with a acute bacterial skin and skin structure infections market share, detailed acute bacterial skin and skin structure infections market segments, market trends and opportunities, and any further data you may need to thrive in the acute bacterial skin and skin structure infections industry. This acute bacterial skin and skin structure infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute bacterial skin and skin structure infections market size has grown rapidly in recent years. It will grow from $11.75 billion in 2024 to $13.03 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to healthcare industry innovation, economic factors, patient population trends, evolving diagnostic methods, clinical trial innovation.
The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $18.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment.
The anticipated surge in the prevalence of skin infections is poised to drive the growth of the market The increasing prevalence of skin infections is anticipated to drive the growth of the acute bacterial skin and skin structure infections market in the future. Skin infections occur when microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, resulting in various symptoms and discomfort. The rise in skin infections generates a heightened demand for therapeutic solutions, antibiotics, and innovative treatments to manage acute bacterial and skin structure infections, ensuring that patients have access to optimal care and outcomes. For example, in March 2023, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that approximately 1.8 billion people worldwide suffer from skin conditions at any given time. Neglected tropical diseases (NTDs) account for about 10% of these cases, with fungal infections representing 34% and bacterial infections 23%, often leading to significant mortality rates. Therefore, the rising prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market.
The increasing prevalence of chronic diseases is also anticipated to boost the growth of the acute bacterial skin and skin structure infections market in the coming years. Chronic diseases are characterized by long-term medical conditions that progress slowly and persist over an extended period, often lasting for years or a lifetime. The growth of chronic diseases contributes to the acute bacterial skin and skin structure infections market by heightening the risk of bacterial skin infections, necessitating increased treatments, hospitalizations, specialized care, research, public awareness, healthcare spending, and tailored interventions for affected individuals. As an illustration, the World Health Organization reported in September 2022 that 74% of the 41 million global deaths caused by non-communicable diseases (NCDs) or chronic diseases annually. The deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the increasing prevalence of chronic diseases is a driving force behind the growth of the acute bacterial skin and skin structure infections market.
Major companies operating in the acute bacterial skin and skin structure infections market are strategically focusing on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge. Dalbonova is a single-dose therapy designed for convenience and effectiveness, allowing patients to achieve desired results with a potent 1500 mg dose administered once. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). This injection reduces the risk of hospital-acquired diseases by offering a single-dose treatment and eliminating the need for hospital admissions. It is designed to treat ABSSSI caused by certain gram-positive microorganisms in patients of all ages, including newborns.
In July 2023, Melinta Therapeutics, a pharmaceutical company based in the U.S., partnered with the Biomedical Advanced Research and Development Authority (BARDA) to advance two FDA-approved antibiotics, Baxdela and Minocin, for use in pediatric patients. This collaboration aims to enhance Melinta's pipeline in hematology by leveraging Imago BioSciences' innovative therapies for myeloproliferative neoplasms and other bone marrow diseases, thereby expanding its ability to provide breakthrough treatments for patients facing these serious conditions. The Biomedical Advanced Research and Development Authority is a U.S. government agency focused on developing and acquiring medical countermeasures to safeguard the nation against public health threats.
Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratorios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the acute bacterial skin and skin structure infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The acute bacterial skin and skin structure infections market consists of revenues earned by entities by providing services such as diagnostic testing, surgical procedures for abscess drainage or debridement, inpatient and outpatient healthcare services, and home healthcare and wound care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute bacterial skin and skin structure infections market also includes sales of wound dressings and bandages, medical devices for wound care, vaccines, hydrogen peroxide, and fusidic acid. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Bacterial Skin And Skin Structure Infections Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute bacterial skin and skin structure infections market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acute bacterial skin and skin structure infections ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute bacterial skin and skin structure infections market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.